Transforming precision immunotherapy through next-generation TCR-T platforms that selectively target mutant TP53 — the most common genetic driver in human cancer.
Our Vision:
To redefine cancer treatment by unlocking the full potential of the immune system to recognize and eradicate p53-mutant tumors.
OncoVanta Therapeutics pioneers innovative TCR-T cell therapies that specifically target mutant TP53 cancers. Our mission is to revolutionize cancer treatment through the development of safe, scalable, and effective immunotherapies. We are committed to advancing the science of cancer care, ensuring that patients receive therapies that are tailored to their unique genetic profiles. Our team of experts is dedicated to transforming lives by providing cutting-edge solutions that enhance the efficacy of cancer treatment.
A Platform Poised for Scalable Value Creation
OncoVanta’s early milestones position it for exponential valuation growth as we advance from preclinical validation to clinical readiness.
Precision therapy targeting TP53 R175H mutation.
Roman Owens is the Founder and CEO of OncoVanta Therapeutics, leading the company’s strategic vision to advance mutant p53-targeted TCR-T cell therapies. With a background in finance, engineering, and biotechnology, he integrates business strategy with translational science to drive innovation. Roman holds an M.B.A. from Howard University and has extensive experience in business development, analytics, and systems engineering across the healthcare and financial sectors.
Dr. Caimei Zhang is the Co-Founder and Lead Principal Investigator at OncoVanta Therapeutics, where she leads scientific development of the company’s TCR-T cell therapy programs targeting mutant p53. With over 15 years of research experience in cellular immunotherapy, Dr. Zhang brings deep expertise in CAR-T and NK cell engineering, tumor immunology, and translational oncology.
Dr. Zhang earned her Ph.D. in Cell Biology from Shanghai JiaoTong University School of Medicine. Her research has contributed to several peer-reviewed publications and patents in immunotherapy and cardiovascular regeneration.
Dr. Tamaro Hudson is a translational cancer biologist and Associate Professor at Howard University College of Medicine. As Co-Founder and Chief Scientific Officer of OncoVanta Therapeutics, he leads the company’s preclinical and translational programs advancing mutant p53-targeted TCR-T cell therapies. His research focuses on molecular mechanisms and biomarkers driving prostate and solid tumor progression, with an emphasis on precision oncology and health equity.
Dedicated research administrator with a passion for innovation. Joyce Terry is an experienced administrator and educator with more than 25 years of leadership in organizational management, nonprofit programs, and education. As Research Administrator at OncoVanta Therapeutics, she supports grant development, compliance, and partnerships for translational research initiatives. Joyce previously served as Principal of Cornerstone Academy and Executive Pastor at Trust Ministries, where she secured major public grant funding. She holds a Master’s in Leadership Education and is completing her Doctor of Business Administration at Indiana Wesleyan University.
